Cargando…

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy

BACKGROUND: There is legitimate concern that minority drug-resistant mutants may be selected during the initial HIV-1 RNA decay phase following antiretroviral therapy initiation, thus undermining efficacy of treatment. The goal of this study was to characterize viral resistance emergence and address...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noguera-Julian, Marc, Casadellà, Maria, Pou, Christian, Rodríguez, Cristina, Pérez-Álvarez, Susana, Puig, Jordi, Clotet, Bonaventura, Paredes, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867623/ https://www.ncbi.nlm.nih.gov/pubmed/24304606 http://dx.doi.org/10.1186/1743-422X-10-350

Ejemplares similares

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
por: Serrao, Erik, et al.
Publicado: (2009)

Unprocessed Viral DNA Could Be the Primary Target of the HIV-1 Integrase Inhibitor Raltegravir
por: Ammar, Farah F., et al.
Publicado: (2012)

HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization
por: Pou, Christian, et al.
Publicado: (2013)

Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
por: Fernández-Caballero, Jose Ángel, et al.
Publicado: (2016)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
por: Machado, Lucas de Almeida, et al.
Publicado: (2019)

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death
por: Casadellà, Maria, et al.
Publicado: (2017)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death
por: Casadellà Fontdevila, Maria, et al.
Publicado: (2014)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

Evolution of the gut microbiome following acute HIV-1 infection
por: Rocafort, Muntsa, et al.
Publicado: (2019)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions
por: Reigadas, Sandrine, et al.
Publicado: (2010)

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
por: Doyle, Tomas, et al.
Publicado: (2015)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

HIV-2 Integrase Polymorphisms and Longitudinal Genotypic Analysis of HIV-2 Infected Patients Failing a Raltegravir-Containing Regimen
por: Cavaco-Silva, Joana, et al.
Publicado: (2014)

Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance
por: Fun, Axel, et al.
Publicado: (2018)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

Multimodal Functionalities of HIV-1 Integrase
por: Engelman, Alan N., et al.
Publicado: (2022)

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gp(high) cells and correlates with HIV-1 viral load
por: Minuesa, Gerard, et al.
Publicado: (2016)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

Raltegravir: The evidence of its therapeutic value in HIV-1 infection
por: Ramkumar, Kavya, et al.
Publicado: (2010)

Probiotic effects on immunity and microbiome in HIV-1 discordant patients
por: Blázquez-Bondia, Carlos, et al.
Publicado: (2022)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

HIV-1 Integrase-DNA Recognition Mechanisms
por: Kessl, Jacques J., et al.
Publicado: (2009)

HIV-1 integrase SUMOylation and viral replication
por: Zamborlini, Alessia, et al.
Publicado: (2011)

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
por: Charpentier, Charlotte, et al.
Publicado: (2010)

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013)

Modelling HIV-1 2-LTR dynamics following raltegravir intensification
por: Luo, Rutao, et al.
Publicado: (2013)

Correction to 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_novju365s97tv1q99369cuhq27